Bio Techne Gains 11.45% to $70.33
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 hours ago
0mins
Notable gainers among liquid option names this morning include Bio Techne (TECH) $70.33 +11.45, Sandisk Corporation (SNDK) $2133.50 +219.04, Micron (MU) $1148.07 +99.56, PerkinElmer Inc (RVTY) $112.91 +7.28, and Xylem (XYL) $117.97 +5.93.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TECH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TECH
Wall Street analysts forecast TECH stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 58.875
Low
60.00
Averages
66.14
High
72.00
Current: 58.875
Low
60.00
Averages
66.14
High
72.00
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bio-Techne Soars Over 20% on Merck Acquisition News
- Acquisition News Boosts Stock: Bio-Techne Corp. (TECH) shares surged over 20% following the announcement of its acquisition by Merck KGaA for $73 per share, representing a total enterprise value of approximately $11.3 billion, which is a 36% premium to its one-month volume weighted average price, indicating strong market confidence in the deal.
- Strong Financial Performance: Bio-Techne generated over $1.2 billion in net sales for fiscal year 2025, and the acquisition is expected to immediately enhance Merck KGaA's profitability, improving both its Life Science business and overall EBITDA pre-margin, showcasing the strategic value of the acquisition.
- Cost Savings Expectations: Merck KGaA anticipates achieving approximately €140 million in annual cost savings by the third year post-transaction, indicating significant operational efficiency gains that will further bolster the company's financial health.
- Transaction Timeline: The deal is expected to close by late 2026 or early 2027, marking a significant integration for Bio-Techne in the biotech sector, which may influence future market competitive dynamics.
See More
US Stocks Close Mixed: Tech Stocks Weigh on Market
- Tech Stock Weakness: Apple’s stock fell over 6% after raising prices on Macs, iPads, and Vision Pro to offset memory chip shortages, significantly dragging down the S&P 500 and Dow Jones Industrial Average, highlighting the vulnerability of tech stocks in the current market.
- Chip Sector Strength: Micron Technology’s forecast of $50 billion in Q4 revenue, well above the $43.24 billion consensus, led to a 15% stock surge, bolstering investor confidence in the AI sector and potentially driving growth across related industries.
- Positive Economic Data: Initial jobless claims fell to 215,000, below the expected 225,000, indicating a robust labor market, while May personal spending and income exceeded expectations, suggesting sustained consumer spending that could support the stock market.
- International Market Rally: European and Asian stock markets closed higher, with the Euro Stoxx 50 and Japan’s Nikkei 225 rising by 0.85% and 4.61%, respectively, reflecting global optimism about the US economic recovery, which may provide support for US stocks.
See More
Bio-Techne Shares Surge 20.09% on Merck KGaA Acquisition Offer
- Significant Stock Surge: Bio-Techne (TECH) shares rose by 20.09% to close at $70.67, primarily driven by Merck KGaA's $73-per-share cash acquisition offer, indicating strong market optimism regarding the deal.
- Volume Spike: Today's trading volume reached 51.3 million shares, approximately 1,378% above the three-month average of 3.5 million shares, reflecting heightened investor interest and engagement with the acquisition news.
- Acquisition Context: Following activist investor Ananym Capital Management's announcement of a stake in Bio-Techne and its push for a sale, Merck KGaA's acquisition proposal has clarified Bio-Techne's market outlook, expected to revitalize Merck KGaA's product pipeline.
- Synergy Expectations: Merck KGaA anticipates achieving over $150 million in annual cost synergies within three years, based on last year's net income of approximately $3 billion, which is projected to add about 5% to its bottom line, further enhancing its competitive position in the biotech sector.
See More
Bio-Techne Shares Surge on Merck KGaA Acquisition Proposal
- Significant Price Surge: Bio-Techne's stock closed at $70.67, reflecting a 20.02% increase primarily driven by Merck KGaA's $73-per-share cash acquisition proposal, indicating strong market optimism regarding the deal's potential success.
- Trading Volume Spike: The trading volume reached 51.3 million shares, which is approximately 1,378% above the three-month average of 3.5 million shares, highlighting heightened investor interest and market activity surrounding the acquisition updates.
- Industry Context: In 2026, healthcare deals have totaled $419 billion, marking the highest level since 2021, and Bio-Techne's consistent growth and profitability will enhance Merck KGaA's pipeline, with anticipated annual cost synergies exceeding $150 million.
- Investor Caution: Despite Bio-Techne's strong performance, the Motley Fool analyst team did not include it in their current list of top investment stocks, advising investors to exercise caution when making investment decisions.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Bio-Techne Corporation and Apogee Therapeutics for potential violations of federal securities laws and fiduciary duties, with Bio-Techne's sale to Merck KGaA at $73.00 per share in cash being a focal point.
- Shareholder Rights: Shareholders of Bio-Techne and Apogee Therapeutics are encouraged to contact the firm to learn about their rights and options, with Apogee's sale price set at $135.11 per share in cash, highlighting the firm's commitment to shareholder interests.
- Merger Transaction Impact: The merger between Boundless Bio and Serapha Bio is expected to result in Boundless Bio shareholders owning approximately 3.7% of the combined entity, while Chicago Atlantic Real Estate Finance's merger with Chicago Atlantic BDC will allow REFI shareholders to hold about 50.5% of the merged company, indicating significant changes in shareholder structure.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no upfront costs for clients, aiming to support investors affected by securities fraud and corporate misconduct, thereby emphasizing its role in protecting investor rights.
See More
US Stocks Rise Slightly, Led by Chipmakers
- Chipmaker Surge: US stocks rose today, led by Micron Technology's forecast of $50 billion in Q4 revenue, significantly above the $43.24 billion consensus, resulting in an 11% stock price increase and bolstering the bullish case for AI trades.
- Positive Economic Indicators: US economic data revealed an upward revision of Q1 GDP to 2.1%, surpassing the expected 1.6%, while weekly initial jobless claims fell by 12,000 to 215,000, indicating a robust labor market that enhances market confidence.
- Improved Inflation Expectations: The May core PCE price index rose 3.4% year-over-year, aligning with expectations, and the 10-year Treasury yield dropped to a 6-week low of 4.36%, providing support for stocks and alleviating investor concerns about rate hikes.
- Apple's Stock Decline: Despite overall market gains, Apple's stock fell over 5% after raising prices on Macs and iPads to offset memory chip shortages, which limited the broader market's upward momentum.
See More
Bio-Techne Soars Over 20% on Merck Acquisition News
- Acquisition News Boosts Stock: Bio-Techne Corp. (TECH) shares surged over 20% following the announcement of its acquisition by Merck KGaA for $73 per share, representing a total enterprise value of approximately $11.3 billion, which is a 36% premium to its one-month volume weighted average price, indicating strong market confidence in the deal.
- Strong Financial Performance: Bio-Techne generated over $1.2 billion in net sales for fiscal year 2025, and the acquisition is expected to immediately enhance Merck KGaA's profitability, improving both its Life Science business and overall EBITDA pre-margin, showcasing the strategic value of the acquisition.
- Cost Savings Expectations: Merck KGaA anticipates achieving approximately €140 million in annual cost savings by the third year post-transaction, indicating significant operational efficiency gains that will further bolster the company's financial health.
- Transaction Timeline: The deal is expected to close by late 2026 or early 2027, marking a significant integration for Bio-Techne in the biotech sector, which may influence future market competitive dynamics.
See More
US Stocks Close Mixed: Tech Stocks Weigh on Market
- Tech Stock Weakness: Apple’s stock fell over 6% after raising prices on Macs, iPads, and Vision Pro to offset memory chip shortages, significantly dragging down the S&P 500 and Dow Jones Industrial Average, highlighting the vulnerability of tech stocks in the current market.
- Chip Sector Strength: Micron Technology’s forecast of $50 billion in Q4 revenue, well above the $43.24 billion consensus, led to a 15% stock surge, bolstering investor confidence in the AI sector and potentially driving growth across related industries.
- Positive Economic Data: Initial jobless claims fell to 215,000, below the expected 225,000, indicating a robust labor market, while May personal spending and income exceeded expectations, suggesting sustained consumer spending that could support the stock market.
- International Market Rally: European and Asian stock markets closed higher, with the Euro Stoxx 50 and Japan’s Nikkei 225 rising by 0.85% and 4.61%, respectively, reflecting global optimism about the US economic recovery, which may provide support for US stocks.
See More
Bio-Techne Shares Surge 20.09% on Merck KGaA Acquisition Offer
- Significant Stock Surge: Bio-Techne (TECH) shares rose by 20.09% to close at $70.67, primarily driven by Merck KGaA's $73-per-share cash acquisition offer, indicating strong market optimism regarding the deal.
- Volume Spike: Today's trading volume reached 51.3 million shares, approximately 1,378% above the three-month average of 3.5 million shares, reflecting heightened investor interest and engagement with the acquisition news.
- Acquisition Context: Following activist investor Ananym Capital Management's announcement of a stake in Bio-Techne and its push for a sale, Merck KGaA's acquisition proposal has clarified Bio-Techne's market outlook, expected to revitalize Merck KGaA's product pipeline.
- Synergy Expectations: Merck KGaA anticipates achieving over $150 million in annual cost synergies within three years, based on last year's net income of approximately $3 billion, which is projected to add about 5% to its bottom line, further enhancing its competitive position in the biotech sector.
See More
Bio-Techne Shares Surge on Merck KGaA Acquisition Proposal
- Significant Price Surge: Bio-Techne's stock closed at $70.67, reflecting a 20.02% increase primarily driven by Merck KGaA's $73-per-share cash acquisition proposal, indicating strong market optimism regarding the deal's potential success.
- Trading Volume Spike: The trading volume reached 51.3 million shares, which is approximately 1,378% above the three-month average of 3.5 million shares, highlighting heightened investor interest and market activity surrounding the acquisition updates.
- Industry Context: In 2026, healthcare deals have totaled $419 billion, marking the highest level since 2021, and Bio-Techne's consistent growth and profitability will enhance Merck KGaA's pipeline, with anticipated annual cost synergies exceeding $150 million.
- Investor Caution: Despite Bio-Techne's strong performance, the Motley Fool analyst team did not include it in their current list of top investment stocks, advising investors to exercise caution when making investment decisions.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Bio-Techne Corporation and Apogee Therapeutics for potential violations of federal securities laws and fiduciary duties, with Bio-Techne's sale to Merck KGaA at $73.00 per share in cash being a focal point.
- Shareholder Rights: Shareholders of Bio-Techne and Apogee Therapeutics are encouraged to contact the firm to learn about their rights and options, with Apogee's sale price set at $135.11 per share in cash, highlighting the firm's commitment to shareholder interests.
- Merger Transaction Impact: The merger between Boundless Bio and Serapha Bio is expected to result in Boundless Bio shareholders owning approximately 3.7% of the combined entity, while Chicago Atlantic Real Estate Finance's merger with Chicago Atlantic BDC will allow REFI shareholders to hold about 50.5% of the merged company, indicating significant changes in shareholder structure.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no upfront costs for clients, aiming to support investors affected by securities fraud and corporate misconduct, thereby emphasizing its role in protecting investor rights.
See More
US Stocks Rise Slightly, Led by Chipmakers
- Chipmaker Surge: US stocks rose today, led by Micron Technology's forecast of $50 billion in Q4 revenue, significantly above the $43.24 billion consensus, resulting in an 11% stock price increase and bolstering the bullish case for AI trades.
- Positive Economic Indicators: US economic data revealed an upward revision of Q1 GDP to 2.1%, surpassing the expected 1.6%, while weekly initial jobless claims fell by 12,000 to 215,000, indicating a robust labor market that enhances market confidence.
- Improved Inflation Expectations: The May core PCE price index rose 3.4% year-over-year, aligning with expectations, and the 10-year Treasury yield dropped to a 6-week low of 4.36%, providing support for stocks and alleviating investor concerns about rate hikes.
- Apple's Stock Decline: Despite overall market gains, Apple's stock fell over 5% after raising prices on Macs and iPads to offset memory chip shortages, which limited the broader market's upward momentum.
See More
